Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amyloidosis × Vinorelbine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 83 Carcinoma, Non-Small-Cell Lung 49 Lung Neoplasms 22 Hodgkin Disease 15 Recurrence 10 Lymphoma 10 Prostatic Neoplasms 7 Triple Negative Breast Neoplasms 6 Neoplasm Metastasis 6 Neoplasms 5 Lymphoma, Non-Hodgkin 4 Lymphoma, Large B-Cell, Diffuse 4 Adenocarcinoma of Lung 4 Sarcoma 3 Rhabdomyosarcoma 3 Mesothelioma, Malignant 3 Mesothelioma 3 Breast Neoplasms, Male 3 Ovarian Neoplasms 2 Neuroblastoma 2 Multiple Myeloma 2 Melanoma 2 Lymphoma, Large-Cell, Anaplastic 2 HER2-negative Breast Cancer 2 Fallopian Tube Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Brain Neoplasms 2 Advanced Breast Cancer 2 Waldenstrom Macroglobulinemia 1 Vinorelbine 1

Interventions

Dexamethasone 5 Cyclophosphamide 4 Bortezomib 4 Melphalan 3 Lenalidomide 2 Doxycycline 2 Calcium Dobesilate 2 ixazomib 1 daratumumab 1 birtamimab 1 belantamab mafodotin 1 Vinorelbine 1 Thalidomide 1 Gemcitabine 1 Etoposide 1 Etanercept 1 Doxorubicin 1 Cisplatin 1 Antineoplastic Protocols 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02791373 2018-04-03

ViGeM

Insel Gruppe AG, University Hospital Bern

Phase 2 Completed

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡